Aevum Biosystems combines synthetic gene circuit design, adaptive bioprocess optimization, and modular delivery to compress the distance between biological insight and therapeutic reality.
Each capability within the AVB Platform is designed to interoperate. Gene circuit outputs inform delivery optimization; bioprocess ML models are trained on delivery-adjusted expression data. The result is a compounding advantage that accelerates every program on the platform.
Proprietary synthetic gene circuits that sense, compute, and respond to complex intracellular signals with sub-nanomolar precision. Our AGCA platform enables programmable cell behavior without off-target genomic disruption.
Machine learning models trained on 2.3 million fermentation runs continuously optimize yield, purity, and scalability. Real-time adaptive control reduces upstream bioprocess development cycles from 18 months to under 6.
A library of 340+ validated delivery vectors engineered for tissue-specific tropism. Our lipid nanoparticle and viral vector libraries are de-immunized and scalable for clinical manufacturing under cGMP conditions.
Precisely engineer immune cell phenotypes through combinatorial cytokine and checkpoint modulation. Our ISF platform has demonstrated durable CAR-T persistence improvements of 4.7× in exhaustion-prone solid tumor models.
Six therapeutic programs spanning oncology, neurology, cardiovascular medicine, and rare disease. All programs leverage core AVB Platform capabilities and benefit from our proprietary bioprocess infrastructure.
| Program | Indication | Stage | Partner |
|---|---|---|---|
| AVB-101KRAS G12C · Solid Tumors | Oncology | Internal | |
| AVB-203SCN1A · Dravet Syndrome | Neurology | Novartis Collaboration | |
| AVB-318PCSK9 · Familial Hypercholesterolemia | Cardiovascular | Internal | |
| AVB-442IL-17A · Psoriatic Arthritis | Immunology | Sanofi Option | |
| AVB-561OTC Deficiency · Urea Cycle | Rare Disease | Internal | |
| AVB-674TDP-43 · ALS/FTD | Neurology | Academic License |
"We don't engineer biology around what's convenient. We engineer it around what's true."
Every AVB Platform capability emerged from years of fundamental research published in peer-reviewed journals. Our scientific founders remain active contributors to the academic literature, maintaining a feedback loop between basic discovery and translational application that is rare in biotech.
Our 47 publications span synthetic biology, gene therapy delivery, bioprocess control, and computational immunology — a breadth that reflects the integrative nature of our platform and the depth of our scientific team.
Aevum Biosystems was founded by scientists who spent careers at institutions where rigor is non-negotiable. Our leadership team holds 12 collective patents, 47 publications, and has structured over $2.1B in biopharma transactions.
Former Group Leader at the Broad Institute. 18 years in synthetic biology and gene therapy. PhD from MIT, postdoctoral fellowship at Stanford School of Medicine.
Led CRISPR engineering programs at Editas Medicine. Expert in non-viral delivery and gene circuit design. 47 peer-reviewed publications, H-index 38.
Built the bioprocess ML stack at Genentech. Holds 12 patents in adaptive fermentation control. MSc in Biomedical Engineering, Imperial College London.
Structured over $2.1B in biopharma licensing deals. Former Managing Director at JP Morgan Healthcare. MBA from Wharton with deep expertise in gene therapy transactions.
Established the CAR-T solid tumor program at Iovance. Deep expertise in T cell exhaustion mechanisms and combinatorial cytokine engineering. Appointed KOL at ASH 2023.
Formerly at DeepMind Health. Built protein structure prediction pipelines that accelerated target identification by 6×. Expert in multi-omics integration and AI-driven hit identification.
Whether you're exploring licensing agreements, co-development opportunities, or scientific collaborations — we want to hear from you. Reach out to our business development team or connect directly with our scientific leads.